How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Exclusive: Campaign group calls on institutional shareholders to vote against re-election of bosses overseeing net zero row-back Bank chairs who water down their lenders’ climate commitments this year ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

A team of researchers has found a way to steer the output of large language models by manipulating specific concepts inside ...